Axonics® CEO Raymond W. Cohen Named Ernst & Young Entrepreneur of the Year® 2020 Award Finalist for Orange County

September 16, 2020 at 9:00 AM EDT

IRVINE, Calif.--(BUSINESS WIRE)--Sep. 16, 2020-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, today announced that Raymond W. Cohen, Axonics CEO, has been named an Ernst & Young Entrepreneur of the Year 2020 Award finalist for Orange County. The Entrepreneur of the Year program honors entrepreneurial business leaders whose vision fosters innovation, growth and prosperity as they build and sustain successful businesses.

Award winners will be announced through a special virtual event on October 6 and will join a community of Entrepreneur of the Year alumni from around the world. This year, entrepreneurs that have provided extraordinary support for their communities, employees and others during the COVID-19 crisis will also be recognized for their resilience and leadership.

Entrepreneur of the Year is one of the preeminent competitive award programs for entrepreneurs and leaders of high-growth companies. The nominees are evaluated based on six criteria, including overcoming adversity; financial performance; societal impact and commitment to building a values-based company; innovation; and talent management. Since its launch, the program has expanded to recognize business leaders in more than 145 cities in over 60 countries around the world.

Raymond W. Cohen said, “It is an honor to be named a finalist for the Entrepreneur of the Year Award in Orange County. Entrepreneurs play a vital role in driving innovation and creating jobs. Given the pandemic and the millions of unemployed, high quality jobs with good healthcare coverage are more important than ever to our society.”

Cohen continued, “Leading Axonics since its founding in late 2013 has been a privilege. Together with my colleagues, we have built a fast-growing company that values diversity, quality, thoughtful innovation, integrity and teamwork. I am proud to share this recognition with our over 400 dedicated employees focused on improving the lives of patients suffering from bladder and bowel dysfunction.”

Regional award winners are eligible for consideration for the Entrepreneur of the Year National Awards, to be announced in November during a virtual awards gala. The Entrepreneur of the Year National Award winner will then move on to compete for the EY World Entrepreneur of the Year™ Award in June 2021.

About Axonics Modulation Technologies, Inc.

Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction. These conditions are caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. Axonics SNM therapy, which has been clinically proven to reduce symptoms and restore pelvic floor function, is now being offered at hundreds of medical centers across the U.S. and in dozens of select hospitals in Western Europe. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. The Axonics System is the first long-lived rechargeable SNM system approved for sale in the world, and the first to gain full-body MRI conditional labeling. For more information, visit

Axonics contact:
Neil Bhalodkar
Investor Relations

Source: Axonics Modulation Technologies, Inc.


We are here to help answer any questions you may have about the Axonics System and Therapy.